Captor Therapeutics ®
News
April 11, 2022
Captor Therapeutics invited to TPD panel at the 8th Annual LSX World Congress 2022
March 23, 2022
Captor Therapeutics named as the most innovative company on the WSE in the Stock Exchange Company of the Year ranking
March 18, 2022
Captor Therapeutics to Present at the 2nd Annual Targeted Protein Degradation Europe Summit 2022
February 25, 2022
Captor Therapeutics announces positive proof-of-concept efficacy in-vivo data for its lead CT-03 program with strong antitumor activity at all doses tested
February 22, 2022
Captor Therapeutics opens State-of-the-Art Proteomics Lab
February 02, 2022
Captor Therapeutics strengthens its scientific team and prepares for the launch of clinical trials in 2023 with the appointment of Dr. Robert Dyjas as Director of Medical Affairs and Clinical Development
January 13, 2022
Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma
December 15, 2021
Captor Therapeutics to attend the 11th Annual LifeSci Partners Corporate Access Event